TG Therapeutics is a biopharmaceutical company focused on developing and delivering medicines for patients with B-cell mediated diseases, including Chronic Lymphocytic Leukemia, non-Hodgkin Lymphoma and Multiple Sclerosis. Co. has B-cell targeted drug candidates in clinical development, ublituximab and umbralisib. Ublituximab is an anti-CD20 monoclonal antibody. Umbralisib is an oral, once daily, dual inhibitor of phosphoinositide-3-kinase-delta and casein kinase-1-epsilon. In early clinical development Co. has an anti-Programmed Death-Ligand 1 monoclonal antibody, an oral Bruton's Tyrosine Kinase inhibitor, and an anti-CD47/CD19 bispecific antibody. The TGTX stock yearly return is shown above.
The yearly return on the TGTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TGTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|